ASCO/CAP guidelines recommend that HER2 status be determined for all invasive breast cancer patients. These guidelines caution that current HER2 testing methods (central IHC and FISH) may be inaccurate in up to 20% of cases.¹

HERmark Breast Cancer Assay precisely quantifies HER2 total protein and HER2 homodimer levels in FFPE. HERmark reclassified up to 25% of samples from a cohort of the FinHer Adjuvant Breast Cancer Study³

† ASCO: American Society of Clinical Oncology.
CAP: College of American Pathologists.

References:
1. College of American Pathologists. HER2 Testing Guidelines. Accessed February 23, 2009.
2. Monogram data on file.
3. Joensuu H, Weidler J, Lie Y, et al. Quantitative measurements of HER2 expression and HER2 homodimers using a novel proximity based assay: comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX.